Johnson & Johnson (JNJ)

From the record

Johnson & Johnson's filings since 2017 show no warning events in the scan: no bankruptcy or receivership notice, no debt default notice, no exchange listing notice, no restatement warning, no auditor change, no material cyber incident and no late-report notice (its current reports).

From the record

Johnson & Johnson's 10 filed years say what it did: revenue went from $72 billion in fiscal 2017 to $94 billion in fiscal 2025, up 3.1% a year; it rose in 8 of 9 years; the deepest fall was 5% from fiscal 2021 to fiscal 2022; net income was positive in 10 of 10 of those years (its annual reports).

From the record

Over the 3 fiscal years to 2025-12-28, Johnson & Johnson's diluted share count shrank about 3.0% a year, and dividends and buybacks returned about 19% of its operating cash flow over 3 years (its filed statements). Its officers and directors filed 29 sales and 1 purchase of their own stock on the open market in the year to 2026-09-30, buying about $258 thousand (their Form 4 filings).

From the record

Return on equity: in the fiscal year ended 2025-12-28, Johnson & Johnson earned about 33 cents of profit for every dollar of shareholders' money, and gross profitability: its products earned about 32 cents per dollar of everything the company owns. Leverage: it owed about 59 cents per dollar of assets, and net share issuance: its share count was unchanged over the year (the filed statements).

From the record

Johnson & Johnson's standing among 315 graded names in its industry family: revenue of $94 billion in fiscal 2025 ranks in the top 1% by size; a net margin of 28.5% ranks in the top 10%; revenue growth of 5.6% a year over the last 3 filed years ranks in the bottom 48% (its annual reports).

From the record

Johnson & Johnson's leadership, from its insiders' filings and its current reports: the chief executive on the record is Duato, Joaquin (CEO and Chairman of the Board, as filed), filing under that title since 2022-01-19, 4.8 years (bottom 46% of its family); the 23 officers and directors filing in the last fifteen months have been on the record a median of 5.9 years (top 43%); 8 officer or director changes were reported on Form 8-K since 2023-11-13, against the 23 people in charge now (top 34%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

From the record

Johnson & Johnson's room to grow, from the newest filed statements (fiscal 2025): cash of $20 billion against debt of $39 billion leaves -9.9% of its assets as net cash, bottom 10% of its family; cash from operations less capital spending is 20.9% of revenue (top 12%); a gross margin of 67.9% (bottom 47%); research spending of 15.6% of revenue (bottom 20%) (its annual report).

From the record

Johnson & Johnson's growth drivers, from the filed years to fiscal 2025: revenue grew 5.6% a year over the last three filed years against 3.1% over all 10, speeding up (top 25% of its family); the newest year grew 6.1% (bottom 48%); research spending grew 1.2% a year (bottom 49%); capital spending grew 6.4% a year (top 32%) (its annual reports). Johnson & Johnson reported 2 lines of business in fiscal 2025: Innovative Medicine at $60 billion (64%), Med Tech at $34 billion (36%); 2 of 2 grew against the year before (its annual report).

From the record

Johnson & Johnson's newest year against its own record: revenue of $94 billion in fiscal 2025 came in 0.6% above the $94 billion its prior three years' pace pointed to (top 44% of its family); net income of $27 billion against a prior three-year average of $22 billion (top 47%); a net margin of 28.5% against 26.5% before (bottom 39%) (its annual reports).